Raets Lore, Beunen Kaat, Benhalima Katrien
Department of Clinical and Experimental Endocrinology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
Department of Endocrinology, University Hospital Gasthuisberg, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
J Clin Med. 2021 Mar 18;10(6):1257. doi: 10.3390/jcm10061257.
The incidence of gestational diabetes mellitus (GDM) is increasing worldwide. This has a significant effect on the health of the mother and offspring. There is no doubt that screening for GDM between 24 and 28 weeks is important to reduce the risk of adverse pregnancy outcomes. However, there is no consensus about diagnosis and treatment of GDM in early pregnancy. In this narrative review on the current evidence on screening for GDM in early pregnancy, we included 37 cohort studies and eight randomized controlled trials (RCTs). Observational studies have shown that a high proportion (15-70%) of women with GDM can be detected early in pregnancy depending on the setting, criteria used and screening strategy. Data from observational studies on the potential benefit of screening and treatment of GDM in early pregnancy show conflicting results. In addition, there is substantial heterogeneity in age and BMI across the different study populations. Smaller RCTs could not show benefit but several large RCTs are ongoing. RCTs are also necessary to determine the appropriate cut-off for HbA1c in pregnancy as there is limited evidence showing that an HbA1c ≥6.5% has a low sensitivity to detect overt diabetes in early pregnancy.
全球范围内,妊娠期糖尿病(GDM)的发病率正在上升。这对母亲和后代的健康有重大影响。毫无疑问,在孕24至28周期间筛查GDM对于降低不良妊娠结局的风险很重要。然而,关于孕早期GDM的诊断和治疗尚无共识。在这篇关于孕早期GDM筛查现有证据的叙述性综述中,我们纳入了37项队列研究和8项随机对照试验(RCT)。观察性研究表明,根据环境、所用标准和筛查策略,在孕早期可检测出高比例(15%-70%)的GDM女性。关于孕早期GDM筛查和治疗潜在益处的观察性研究数据显示出相互矛盾的结果。此外,不同研究人群在年龄和体重指数方面存在很大异质性。较小规模的RCT未能显示出益处,但几项大型RCT正在进行中。由于仅有有限证据表明糖化血红蛋白(HbA1c)≥6.5%在孕早期检测显性糖尿病的敏感性较低,因此RCT对于确定孕期HbA1c的合适切点也很有必要。